Almac Group today announces the release of the company’s 2023 Corporate Social Responsibility report, which highlights Almac’s progress and commitments to our people, our planet, and the communities in which we operate.
The report also provides insights into Almac’s client delivery across the drug development pipeline, and a look into the company’s ambitious growth strategy posed to sustain best-in-class service offerings to clients and bolster innovation.
Alan Armstrong, Chairman and CEO, commented: “Almac’s mission to advance human health is the driving force behind everything we do as an organisation. We are exceedingly proud of how we have delivered on our responsibilities this year—particularly, our progress towards our commitment to reach net zero by 2045, our further investment in health and wellbeing offerings for our people, and our contributions to our communities.
“We are also proud to recognise the essential role our colleagues have played in our success – by living out our mission each day, they are collectively impacting human health across the globe.”
In 2022, Almac announced a commitment to reach net zero by 2045, and to reduce Scope 1 and Scope 2 emissions by 50 percent by 2030. Highlights from this year’s report that support the company’s net zero ambition include:
• Joining the Science Based Targets Initiative (SBTi), which defines and promotes best practice in science-based target setting for the reduction of greenhouse gases
• Appointing a dedicated Global Energy Manager to drive actions to support Almac’s net zero commitment, and develop business improvement initiatives across the globe
Almac is also wholly committed to supporting, developing, and rewarding our people, as well as making a positive and lasting contribution to our communities. Highlights from the last year in these areas include:
• 2,000 employees received recognition awards
• Reaching 100% of employees with health and wellbeing programme
• Supporting 40 different charities through global philanthropy
• Reaching an estimated 10,000 post-primary pupils through in-person and virtual outreach programmes.
Almac’s CSR strategy is designed to align priorities with the United Nations’ Sustainable Development Goals (SDGs) and the Pharmaceutical Supply Chain Initiative (PSCI).
Read the full report here – https://www.almacgroup.com/corporate-social-responsibility